BRD2 and non-small cell lung carcinoma: This report shows a novel co‐targeting strategy by combined inhibition of BRD2 through BET inhibitor JQ1 and FTH1depletion in unresponsive non‐small cell lung cancer cells (NSCLC) to JQ1.